3 Long-term Income Plays: Legal And General Group Plc, GlaxoSmithKline Plc And SSE PLC

Legal & General Group Plc (LON: LGEN), GlaxoSmithKline Plc (LON: GSK) and SSE PLC (LON: SSE) will bring joy to long-term income seekers, says Harvey Jones.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Share price growth can give investors a real buzz in the short-term, but it’s the dividend income that brings the most satisfying long-term rewards. If you can generate 4% or 5% a year and use that to buy more shares in the same company, eventually you will be talking real money.

Up to three-quarters of your long-term returns will come from dividend income. The key phrase here is long-term. Here are three income stocks with staying power.

Legal & General Group

Over the last five years, FTSE-listed insurance giant Legal & General Group (LSE: LGEN) has doubled your money in share price growth alone. The last year has been stickier with the stock down 15%, but that won’t worry long-term income seekers, as L&G currently yields 5.62%. In fact, it works in their favour, because if they re-invest their dividends they’ll pick up more stock at the lower price.

Somebody who invested five years ago, when the stock traded at 116p (against 238p today), is effectively getting a yield of 11.5% on their original investment. FTSE insurers have all been hit by wider stock market uncertainty yet L&G still has plenty in its favour, as a major presence in three fast-growing areas: low-cost tracker funds, UK workplace auto-enrolment schemes and bulk annuities. Earnings per share (EPS) are forecast to rise 7% this year and 8% in 2016, when the yield is expected to hit an even juicier 6.4%.

GlaxoSmithKline

Investment fashions change but one thing seems eternal: pharmaceutical giant GlaxoSmithKline (LON: GSK) is still the FTSE 100 poster boy for dividend income. Yet even dividend heroes can suffer their moments of misfortune, with the Chinese bribery scandal and more importantly, fears of a patent cliff, hitting investor sentiment. Glaxo has been trying to wean itself off its dependence on respiratory treatment Advair/Seretide, with sales down sharply on generic competition. Moves to diversify into vaccines and consumer health, pharmaceutical products and the HIV franchise, are finally bearing fruit.

Four years of negative EPS are expected to turn positive with a vengeance in 2016, rising 14%. Forecast dividend growth looks less spectacular, but the yield is expected to continue hovering around 5.4%, perfect for investors who like to play the long game.

SSE

Some may think I’m rash by including utility company SSE (LSE: SSE) under the heading “long-term income plays”. Its dividend may yield a juicy 5.83% but there has been talk of a cut as cover gets stretched. SSE has been hit by falling energy prices and increased retail market competition, as disgruntled customers switch from the Big Six energy companies to smaller challengers.

Management has committed to raising its dividend by RPI inflation at least, a commitment it stands by even though EPS are expected to fall from 124.1p in the year to March 2015 to 111.79p this year, a drop of almost 10%. It also warned that dividend cover could range from around 1.2 times to around 1.4 times over the next three years, but the yield is still forecast to hit 6% by March 2018, suggesting fears of a cut are overplayed. It still has its believers: JP Morgan is overweight with a target price of 1,550p, only slightly above today’s 1,515p. That confirms my view: forget growth, SSE is all about the income, and the income is good.

Harvey Jones has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

British flag, Big Ben, Houses of Parliament and British flag composition
Investing Articles

Scottish Mortgage has made a fortune on SpaceX and Tesla! Here are 5 UK stocks it owns

This FTSE 100 investment trust holds 101 growth stocks from around the globe, but only five from the UK. Which…

Read more »

Businessman hand stacking up arrow on wooden block cubes
Investing Articles

I think UK investors are missing out on this overlooked Dow Jones stock

Jon Smith flags a US stock in the Dow Jones index that has a price-to-earnings ratio over half the average,…

Read more »

Shot of an young mixed-race woman using her cellphone while out cycling through the city
Investing For Beginners

2 FTSE 100 shares that could outperform this year regardless of geopolitics

Jon Smith notes the volatile market but explains how to pick FTSE 100 shares that can be fairly insulated to…

Read more »

Man writing 'now' having crossed out 'later', 'tomorrow' and 'next week'
Investing Articles

With share prices rising, is now the time to hold off buying stocks?

Despite share prices rising, Stephen Wright thinks there are still opportunities for investors looking for stocks to consider buying.

Read more »

Smartly dressed middle-aged black gentleman working at his desk
Investing Articles

6% dividend yields and a P/E below 6! Here’s a FTSE 250 bargain share to consider

I love UK shares with low earnings multiples and high dividend yields. So I'm considering buying this cheap-as-chips FTSE 250…

Read more »

A graph made of neon tubes in a room
Investing Articles

Dividends up 36% in 3 years! No wonder BAE Systems is a popular SIPP stock

Mark Hartley takes a closer look at the types of stocks that are popular in a SIPP, from mega-cap UK…

Read more »

Mature black woman at home texting on her cell phone while sitting on the couch
Investing Articles

£10,000 invested in Rolls-Royce shares at the start of the year is now worth…

Rolls-Royce shares have been the darling of the UK stock market in recent years but how have they fared in…

Read more »

Happy couple showing relief at news
Investing Articles

How to turn £10 a day in a Stocks & Shares ISA into £23,857 of passive income!

Looking for ways to make a sustained passive income? Royston Wild explains how the Stocks and Shares ISA could help…

Read more »